Connect with us

Published

on

Shares of the Peter Thiel-backed psychedelic start-up Atai Life Sciences jumped Friday on its first day of trading on Wall Street.

The newly listed Nasdaq stock opened up 40% before pulling back some.

The German biotech’s initial public offering was priced Thursday night at $15 per share, the high end of the expected range. The company, which aims to make psychedelic drugs to treat mental health disorders, raised $225 million at a valuation of $2.3 billion.

Atai is the third psychedelic biotech to go public in the U.S., following in the footsteps of MindMed, which went public on the Nasdaq in April, and Founders Fund-backed Compass Pathways, which listed in September. As of Thursday’s close, Compass Pathways was up 26% since its debut, and MindMed, which just announced its CEO’s resignation, was down about 19% since its IPO.

Each biotech is developing therapies using the psychedelic mushroom compound psilocybin, LSD, and MDMA derivatives to treat addiction and mental illnesses such as depression, anxiety, schizophrenia and traumatic brain injury. Three years after its founding, Atai Life Sciences has 10 therapeutic programs in its pipeline, each at various stages of clinical trials.

Atai founder and Chairman Christian Angermayer said on CNBC’s “Squawk Box” on Friday, “The world we’re building is a bad place for our brain, so mental health issues will go up. But I do think we have some real shots in our portfolio to end the mental health crisis.”

Investor interest in psychedelic treatments has grown alongside burgeoning interest in these therapies from the medical community.

Johns Hopkins University, Yale University, the University of California, Berkeley, and the Icahn School of Medicine are among the centers studying psychedelics and psychology. Recent studies establishing MDMA’s promise in treating post-traumatic stress disorder and the efficacy of psilocybin, a hallucinogenic chemical found in psychedelic mushrooms, in treating drug-resistant depression have only heightened interest in the space.

Angermayer was an early investor in Compass Pathways, and his own company Atai serves as a holding company for various psychedelic start-ups pursuing alternative treatments for mental illness. He told CNBC on Friday that new-age biotechs are building on centuries of practice in shamanistic cultures and religions.

There are currently federal restrictions for psychedelic mushrooms, MDMA — commonly known as molly or ecstasy — and LSD around the world. However, Oregon last year became the first U.S. state to legalize psychedelics for therapeutic use. Residents in Washington, D.C., also recently voted in support of decriminalizing the use of psychedelics for medicinal purposes.

Atai Life Sciences at the Nasdaq for its IPO, June 18, 2021.
Source: Nasdaq

Angermayer is betting that federal approval of these drugs for therapeutic use could make a huge difference for those suffering from mental illness. “They are very, very powerful medications, but they have to be taken under supervision. … You will be tripping while you are sitting with your therapist.”

Atai Life Sciences is backed by the billionaire investor Thiel, as well as Mike Novogratz’s Galaxy Investments and Angermayer’s own Apeiron Investment Group, among others.

According to venture capital tracker CB Insights, VC deals in psychedelics have risen substantially in the last three years: 2018 and 2019 saw less than $100 million of venture capital invested in psychedelic start-ups, but 2020 saw $346 million. By April 2021, VCs had already invested $329 million in the industry.

It’s no wonder that Atai’s was more than 12 times oversubscribed, according to one market source who asked to remain anonymous due to the nature of the discussion. “A good portion was taken up by existing investors,” the person said, adding that Thiel is the largest existing investor and that he’s “doubled down” in the IPO.

Investment fund Palo Santo said it had taken a notable stake in Atai’s IPO. “There is an urgent need to address our broken mental healthcare system,” Daniel Goldberg, co-founder of Palo Santo, said in a statement. “We believe psychedelics will expand treatment options and transform the outdated system.”

Atai submitted an S-1 filing to the Securities and Exchange Commission in April that showed it raised an aggregate of $362.3 million from private investors at that point.

The company, which describes itself as a drug development platform, was set up to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions.

Atai, which has roughly 50 staff members in offices across Berlin, New York and San Diego, is currently partnered with 14 companies focusing on drug development and other technologies.

In exchange for a majority stake in the drugs and technologies they’re developing, Atai helps the scientists raise money, work with regulators and conduct clinical trials. None of Atai’s drugs have been formally approved by regulators to date.

Thiel made an $11.9 million investment in Atai through his venture firm, Thiel Capital, in November.

“Atai’s great virtue is to take mental illness as seriously as we should have been taking all illness all along,” Thiel, who co-founded Palantir and PayPal, said in a statement shared with CNBC at the time. “The company’s most valuable asset is its sense of urgency.”

Continue Reading

Technology

Google agrees to pay Texas $1.4 billion data privacy settlement

Published

on

By

Google agrees to pay Texas .4 billion data privacy settlement

A Google corporate logo hangs above the entrance to the company’s office at St. John’s Terminal in New York City on March 11, 2025.

Gary Hershorn | Corbis News | Getty Images

Google agreed to pay nearly $1.4 billion to the state of Texas to settle allegations of violating the data privacy rights of state residents, Texas Attorney General Ken Paxton said Friday.

Paxton sued Google in 2022 for allegedly unlawfully tracking and collecting the private data of users.

The attorney general said the settlement, which covers allegations in two separate lawsuits against the search engine and app giant, dwarfed all past settlements by other states with Google for similar data privacy violations.

Google’s settlement comes nearly 10 months after Paxton obtained a $1.4 billion settlement for Texas from Meta, the parent company of Facebook and Instagram, to resolve claims of unauthorized use of biometric data by users of those popular social media platforms.

“In Texas, Big Tech is not above the law,” Paxton said in a statement on Friday.

“For years, Google secretly tracked people’s movements, private searches, and even their voiceprints and facial geometry through their products and services. I fought back and won,” said Paxton.

“This $1.375 billion settlement is a major win for Texans’ privacy and tells companies that they will pay for abusing our trust.”

Google spokesman Jose Castaneda said the company did not admit any wrongdoing or liability in the settlement, which involves allegations related to the Chrome browser’s incognito setting, disclosures related to location history on the Google Maps app, and biometric claims related to Google Photo.

Castaneda said Google does not have to make any changes to products in connection with the settlement and that all of the policy changes that the company made in connection with the allegations were previously announced or implemented.

“This settles a raft of old claims, many of which have already been resolved elsewhere, concerning product policies we have long since changed,” Castaneda said.

“We are pleased to put them behind us, and we will continue to build robust privacy controls into our services.”

Continue Reading

Technology

Virtual chronic care company Omada Health files for IPO

Published

on

By

Virtual chronic care company Omada Health files for IPO

Omada Health smart devices in use.

Courtesy: Omada Health

Virtual care company Omada Health filed for an IPO on Friday, the latest digital health company that’s signaled its intent to hit the public markets despite a turbulent economy.

Founded in 2012, Omada offers virtual care programs to support patients with chronic conditions like prediabetes, diabetes and hypertension. The company describes its approach as a “between-visit care model” that is complementary to the broader health-care ecosystem, according to its prospectus.

Revenue increased 57% in the first quarter to $55 million, up from $35.1 million during the same period last year, the filing said. The San Francisco-based company generated $169.8 million in revenue during 2024, up 38% from $122.8 million the previous year.

Omada’s net loss narrowed to $9.4 million during its first quarter from $19 million during the same period last year. It reported a net loss of $47.1 million in 2024, compared to a $67.5 million net loss during 2023.

The IPO market has been largely dormant across the tech sector for the past three years, and within digital health, it’s been almost completely dead. After President Donald Trump announced a sweeping tariff policy that plunged U.S. markets into turmoil last month, taking a company public is an even riskier endeavor. Online lender Klarna delayed its long-anticipated IPO, as did ticket marketplace StubHub.

But Omada Health isn’t the first digital health company to file for its public market debut this year. Virtual physical therapy startup Hinge Health filed its prospectus in March, and provided an update with its first-quarter earnings on Monday, a signal to investors that it’s looking to forge ahead.

Omada contracts with employers, and the company said it works with more than 2,000 customers and supports 679,000 members as of March 31. More than 156 million Americans suffer from at least one chronic condition, so there is a significant market opportunity, according to the company’s filing.

In 2022, Omada announced a $192 million funding round that pushed its valuation above $1 billion. U.S. Venture Partners, Andreessen Horowitz and Fidelity’s FMR LLC are the largest outside shareholders in the company, each owning between 9% and 10% of the stock.

“To our prospective shareholders, thank you for learning more about Omada. I invite you join our journey,” Omada co-founder and CEO Sean Duffy said in the filing. “In front of us is a unique chance to build a promising and successful business while truly changing lives.”

WATCH: The IPO market is likely to pick up near Labor Day, says FirstMark’s Rick Heitzmann

The IPO market is likely to pick up near Labor Day, says FirstMark's Rick Heitzmann

Continue Reading

Technology

Google would need to shift up to 2,000 employees for antitrust remedies, search head says

Published

on

By

Google would need to shift up to 2,000 employees for antitrust remedies, search head says

Liz Reid, vice president, search, Google speaks during an event in New Delhi on December 19, 2022.

Sajjad Hussain | AFP | Getty Images

Testimony in Google‘s antitrust search remedies trial that wrapped hearings Friday shows how the company is calculating possible changes proposed by the Department of Justice.

Google head of search Liz Reid testified in court Tuesday that the company would need to divert between 1,000 and 2,000 employees, roughly 20% of Google’s search organization, to carry out some of the proposed remedies, a source with knowledge of the proceedings confirmed.

The testimony comes during the final days of the remedies trial, which will determine what penalties should be taken against Google after a judge last year ruled the company has held an illegal monopoly in its core market of internet search.

The DOJ, which filed the original antitrust suit and proposed remedies, asked the judge to force Google to share its data used for generating search results, such as click data. It also asked for the company to remove the use of “compelled syndication,” which refers to the practice of making certain deals with companies to ensure its search engine remains the default choice in browsers and smartphones. 

Read more CNBC tech news

Google pays Apple billions of dollars per year to be the default search engine on iPhones. It’s lucrative for Apple and a valuable way for Google to get more search volume and users.

Apple’s SVP of Services Eddy Cue testified Wednesday that Apple chooses to feature Google because it’s “the best search engine.”

The DOJ also proposed the company divest its Chrome browser but that was not included in Reid’s initial calculation, the source confirmed.

Reid on Tuesday said Google’s proprietary “Knowledge Graph” database, which it uses to surface search results, contains more than 500 billion facts, according to the source, and that Google has invested more than $20 billion in engineering costs and content acquisition over more than a decade.

“People ask Google questions they wouldn’t ask anyone else,” she said, according to the source.

Reid echoed Google’s argument that sharing its data would create privacy risks, the source confirmed.

Closing arguments for the search remedies trial will take place May 29th and 30th, followed by the judge’s decision expected in August.

The company faces a separate remedies trial for its advertising tech business, which is scheduled to begin Sept. 22.

Continue Reading

Trending